MarketInOut Stock Screener Log In | Sign Up

Delcath Systems Inc

NASDAQ • Healthcare • Medical Devices • Quote as of 10/30/2026
Delcath Systems Inc stock price and volume chart

Company Profile

IndustryMedical Devices
SectorHealthcare
ExchangeNASDAQ
Market Capitalization487.17 mln
Float32.10 mln
Earnings Date11/09/2026

EPS

0.01
Overpriced

P / E

1,404
Bubble territory

Piotroski F-Score

5 / 9
Neutral

Relative Strength

56 / 100
Slightly ahead

Debt / Equity

0.02
Debt-free

Pre-Tax Margin

1%
Break-even

Business Description

Delcath Systems is a medical company founded in 1988 and based in Queensbury, New York, that develops tools to fight liver cancer in both the United States and Europe. Its main product, sold as HEPZATO KIT in the US and CHEMOSAT in Europe, delivers powerful chemotherapy directly to the liver while limiting the harmful effects that typically spread through the rest of the body. The company is currently running a clinical trial called FOCUS to study how well this approach works in patients with a form of eye cancer that has spread to the liver.

Key Fundamentals

EPS0.01
P/E1,404
ROE0.47
RPS2.64
ROIC-2.01
ROA0.40
EBITDA, mln1.78
EV / EBITDA271
EV / EBIT374
Revenue, mln95.42
EV / Revenue5.06

Quote Details

Last 14.04
Change -0.6 (-4.1%)
Open 14.64
Volume 427,049
Turnover 5,995,768
Average Volume 301,200

Financial Ratios

Pre-Tax Profit Margin1
Leverage Ratio1.13
Current Ratio9.83
Price / Book4.22
Price / Tangible Book4.21
Price / Cash Flow25.72
Price / Free Cash Flow32.21
Debt / Equity0.02
Price / Sales5.88
PEG Ratio1.60

Financial Strength

Altman Z-Score15.71
Piotroski F-Score 5 / 9
Price to Graham Number21.38
Short Ratio5.62
Short % of Float5.91

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -2.64% 36 / 100   
1 Month -8.89% 41 / 100   
2 Months 17.59% 86 / 100   
6 Months 30% 87 / 100   
1 Year 44.44% 81 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog